Company profile
Alzamend Neuro, Inc.
Pipeline2 assets
- AL001AL001 / LISPRO / ionic cocrystal of lithium, proline and salicylate / Neurology/PsychiatryAlzheimer's diseasePhase 2clinical developmentUSBipolar disorderPhase 2clinical developmentUSMajor depressive disorderPhase 2anticipated initiation in 2026US
- ALZN002ALZN002 / E22W / beta-amyloid / autologous mutant-peptide sensitized dendritic-cell therapeutic vaccine / NeurologyMild to moderate dementia of the Alzheimer's typePhase 1/2apaused in 2024; expected to resume by mid-2026US
Latest news4 items
All newsAlzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Presentation / Abstract • Phase 1/2Neuroscience 2026 poster presentation Wed, Nov 18, 2026, 8:00 AM ET
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Presentation / Abstract • Phase 1/2Oral presentation Tue, Sep 29, 2026, 1:35 PM local time